ライフサイエンスコーパス: integrase

1 richia coli generated a fully functional C31 integrase.

2 nt DNA structures by the conserved Cas1-Cas2 integrase.

3 ertion events catalyzed by E. coli Cas1-Cas2 integrase.

4 cation: reverse transcriptase, protease, and integrase.

5 TI on HIV-2 clinical isolates with wild-type integrase.

6 ral cellular and HIV proteins, including the integrase.

7 (CCD) and the C-terminal domain (CTD) of the integrase.

8 ith those observed for prototype foamy virus integrase.

9 plication and is catalyzed by the retroviral integrase.

10 ystem for understanding DDE transposases and integrases.

11 The Wingless/integrase-1 (Wnt) family of protein ligands and their fu

12 ino-acid insertion at codon 231 of the HIV-2 integrase (231INS)-in 6 patients at the virological fail

13 We report single-DNA experiments for Bxb1 integrase, a model SR, where dynamics of individual syna

14 oteins: protease, reverse transcriptase, and integrase; a comparative analysis reveals that NNRTI-ind

15 tructures highlight how small changes in the integrase active site can have notable implications for

16 end after 3' processing, displacing from the integrase active site the DNA 3'-hydroxyl group that is

17 s of Cas4 that closely interact with the two integrase active sites of Cas1, suggesting a mechanism f

18 Retroviral integration proceeds via two integrase activities: 3'-processing of the viral DNA end

19 ere necessary for mouse mammary tumour virus integrase activity.

20 nd host attB sites is promoted by the serine integrase alone, giving recombinant attL and attR sites,

21 factor-p75 (LEDGF/p75)-binding site on HIV-1 integrase, an attractive target for antiviral chemothera

22 a gene cluster encoding for transporters, an integrase and a dioxygenase were involved in BAC biotran

23 ecombination reactions mediated by varphiC31 integrase and its RDF, and use these data as the basis f

24 involves intra-subunit contacts between the integrase and RDF moieties of the fusion protein.

25 DSS3Phi8 also contains the integrase and repressor genes, indicating its potential

26 the forward and reverse reactions using the integrase and the integrase-RDF fusion, respectively.

27 offer novel hypotheses for the enrichment of integrase and transposase genes in cryptic prophages.

28 e used to investigate the link between HIV-1 integrase and viral particle morphogenesis.

29 o recovered known clades of site-promiscuous integrases and identified possible new ones.

30 multi-loci deletions by combining orthogonal integrases and recombinases.

31 logy of multiple mobile DNAs, imprecision of integrases and transposases, and differential activity a

32 otide and 100% protein identity to the VPI-1 integrase, and attachment (att) sites 100% identical to

33 rgeting HIV reverse transcriptase, protease, integrase, and coreceptor CCR5 with EC50's ranging from

34 opies per 10(6) cells), negative for psi and integrase, and negative by the intact proviral DNA assay

35 enzymes-reverse transcriptase, protease, and integrase-and have had the satisfaction of knowing that

36 Active site inhibitors of HIV-1 integrase are clinically validated for the treatment of

37 fferences between transposase and CRISPR-Cas integrase are largely architectural, and it appears that

38 e of the genomic RNA and oligomeric state of integrase are tested.

39 Serine integrases are bacteriophage enzymes that carry out site

40 Serine integrases are emerging as core tools in synthetic biolo

41 Bacteriophage serine integrases are extensively used in biotechnology and syn

42 ir, an antiretroviral agent that targets HIV integrase, as a pharmacologic inhibitor of ALDOA-gamma-a

43 Cas1 integrase associates with Cas2 to insert short DNA fragm

44 ions were each bordered by two nonhomologous integrase attachment (att) sites, which together compris

45 The Phi31 and Bxb1 integrase attP sites flanking the transgene will also en

46 e-reporter system flanked by PhiC31 and Bxb1 integrase attP sites.

47 We have designed a split-intein serine integrase-based system with potential for regulation of

48 egrase hypermultimerization, which precludes integrase binding to genomic RNA and perturbs the morpho

49 ow, Kessl et al. report a second function of integrase: binding to the viral RNA genome in virion par

50 the architecture of a canonical three-domain integrase bound to DNA remained elusive.

51 Retroviral integrase can efficiently utilise nucleosomes for insert

52 We show here that serine integrases can be fused to their cognate RDFs to create

53 ers that engage the core structure via their integrase carboxy-terminal domains.

54 everse transcriptase or its fusion to spacer integrase Cas1.

55 e site-preference of integration by the Cas1 integrase (casposase) encoded by the casposon of the arc

56 Retrovirus integrase catalyses insertions of both ends of the linea

57 Retroviral integrase catalyses the integration of viral DNA into ho

58 Integrase catalyzes two successive magnesium-dependent p

59 e first stage of CRISPR immunity, the Cas1-2 integrase complex captures invader-derived prespacer DNA

60 The conserved Cas1 and Cas2 proteins form an integrase complex consisting of two distal Cas1 dimers b

61 onsequence of the structural symmetry in the integrase complex(2,3).

62 cers into CRISPR loci requires the Cas1/Cas2 integrase complex, frequently in combination with Cas4 e

63 Contrary to the belief that tetrameric integrase components are sufficient to catalyse integrat

64 Here, we show that a mini-integrase comprising the type V-C Cas1 protein alone cat

65 odels of HIV-1 genomic RNA, nucleocapsid and integrase condensed into a mature ribonucleoprotein comp

66 we use click chemistry to label viruses with integrase coupled to eGFP (HIV(IN-eGFP)) and visualize v

67 -processing reaction; this cleavage leads to integrase-dependent integration, highlighted by a 5-bp d

68 atalysis while another pair of non-catalytic integrase dimers bridge between the two viral DNA molecu

69 ic assembly of integrase, in which a pair of integrase dimers engage viral DNA ends for catalysis whi

70 r of prototype foamy virus, and two flanking integrase dimers that engage the core structure via thei

71 icient to catalyse integration, the flanking integrase dimers were necessary for mouse mammary tumour

72 The structure is composed of two core integrase dimers, which interact with the viral DNA ends

73 e a molecular basis for understanding serine integrase directionality.

74 teric integrase inhibitors (ALLINIs), engage integrase distal from the enzyme active site, namely at

75 Serine integrases, DNA site-specific recombinases used by bacte

76 Although structures of the tetrameric integrase-DNA complexes have been reported for integrase

77 of structurally distinct, kinetically stable integrase-DNA product complexes, dependent on the presen

78 The integrase domain of Cas1 was necessary, whereas integrat

79 These discoveries reveal mechanisms by which integrases dramatically manipulate bacterial genomes to

80 tionally discuss the latest advances on anti-integrase drug development for the treatment of AIDS and

81 e relative abundance of the class 1 integron integrase encoding gene (intI1) was observed.

82 site promote aberrant multimerization of the integrase enzyme and are of significant interest as HIV-

83 Interactions between viral RNA and the integrase enzyme are required for HIV-1 particles to bec

84 ores, which exposes the viral genome and the integrase enzyme for degradation in target cells.

85 l-independent losses of the viral genome and integrase enzyme.

86 Retroviral integrase forms a higher order nucleoprotein assembly (i

87 Integrase from HIV-1 and closely related retroviruses sh

88 tegrase-DNA complexes have been reported for integrase from prototype foamy virus featuring an additi

89 port a crystal structure of the three-domain integrase from Rous sarcoma virus in complex with viral

90 The current report examines whether phiC31 integrase functions efficiently in mammalian cells when

91 eukemia virus (MLV) system consisting of MLV-integrase fused to enhanced green fluorescent protein (M

92 raints imposed by the nucleosomal structure, integrase gains access to the scissile phosphodiester bo

93 near the centre of the genome containing an integrase gene and attP.

94 qnrA, sul1, tet(A), tet(W), and tet(X)], the integrase gene of class 1 integrons (intI1), and 16S rRN

95 e chromosomal location as VPI-1, contains an integrase gene with 94% nucleotide and 100% protein iden

96 2000 RealTime HIV-1 assay, which targets the integrase gene.

97 prophages, while tail fiber, transposase and integrase genes are significantly enriched.

98 e ICE integration and to confirm the role of integrase genes intS, intM, and intG in this process.

99 ve virion assembly protein (gp17), the phage integrase (gp29), the endolysin (gp31), the phage repres

100 In most prior studies, phiC31 integrase has been introduced as plasmid DNA or mRNA.

101 The mini-integrase has weak specificity for the CRISPR array.

102 LLINIs inhibit HIV-1 replication by inducing integrase hypermultimerization, which precludes integras

103 er of human immunodeficiency virus 1 (HIV-1) integrase (IN) alterations, referred to as class II subs

104 been implicated in inhibiting homologous HIV integrase (IN) and influenza endonuclease via metal chel

105 n is catalysed by the virally encoded enzyme integrase (IN) and is facilitated by viral genus-specifi

106 rder nucleoprotein complex composed of viral integrase (IN) and the ends of linear vDNA, mediates int

107 g, protease (PR)-reverse transcriptase (RT), integrase (IN) and/or envelope (env) regions.

108 lubility and aggregation properties of HIV-1 integrase (IN) are major obstacles for biochemical and s

109 evidence indicates that inhibition of HIV-1 integrase (IN) binding to the viral RNA genome by allost

110 The integrase (IN) enzyme of retrovirus prototype foamy viru

111 the host genome, catalysed by the retroviral integrase (IN) enzyme.

112 While an essential role of HIV-1 integrase (IN) for integration of viral cDNA into human

113 Retroviral integrase (IN) functions within the intasome nucleoprote

114 Allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are a promising new

115 ridine-based multimerization selective HIV-1 integrase (IN) inhibitors (MINIs) are a distinct subclas

116 The retrovirus integrase (IN) inserts the viral cDNA into the host DNA

117 utants can also rescue a replication-delayed integrase (IN) mutant, and exhibit reduced sensitivity t

118 ORTANCE Recent evidence indicates that HIV-1 integrase (IN) plays a key role during particle maturati

119 NA Pol III, requires the Ty1 element-encoded integrase (IN) protein.

120 replication by binding to the viral-encoded integrase (IN) protein.

121 RTI)-naive and 252 NRTI-treated persons; and integrase (IN) sequences from 236 IN inhibitor (INSTI)-n

122 Ectopic expression of Ty3 integrase (IN) showed that it localized to targets indep

123 of selectivity over RT polymerase (pol) and integrase (IN) strand transfer (ST) inhibitions.

124 Integrase (IN) strand transfer inhibitors (INSTIs) are r

125 otease (PR), reverse transcriptase (RT), and integrase (IN) variability presents a challenge to labor

126 Productive HIV-1 replication requires viral integrase (IN), which catalyzes integration of the viral

127 ation is catalysed by the retrovirus-encoded integrase (IN), which forms a tetramer or octamer comple

128 a principal cellular binding partner of ALV integrase (IN).

129 tion with chromatin and the gamma-retroviral integrase (IN).

130 or the drug-induced multimerization of HIV-1 integrase (IN).

131 The structure shows an octameric assembly of integrase, in which a pair of integrase dimers engage vi

132 capitulates several properties of CRISPR-Cas integrases including site-specificity.

133 RN-SR2 with a truncated variant of the HIV-1 integrase, including both the CCD and CTD.

134 entry inhibitor, but not by raltegravir, an integrase, indicating that only early life cycle events

135 From integrase-induced changes in TPM in the presence or abse

136 ymmetric total synthesis of the potent HIV-1 integrase inhibitor 5 is described.

137 The findings support guidelines recommending integrase inhibitor based regimens in first-line antiret

138 nhibitor-based, 100% (95% CI, 91%-100%); and integrase inhibitor based, 95% (95% CI, 83%-99.4%).

139 ong-acting injectable formulation of the HIV integrase inhibitor cabotegravir (CAB-LA) is currently i

140 ng-acting injectable cabotegravir is a novel integrase inhibitor currently in advanced clinical devel

141 The integrase inhibitor dolutegravir could have a major role

142 The integrase inhibitor dolutegravir is being considered in

143 The integrase inhibitor dolutegravir is currently a preferre

144 n the plasma drug concentration of the viral integrase inhibitor dolutegravir.

145 Besides BMI and ALT, integrase inhibitor exposure was associated with higher

146 ir recommended as a preferred or alternative integrase inhibitor for pregnant women living with HIV.

147 d virological failure with resistance in the integrase inhibitor group compared with three participan

148 252 (87%) women in the integrase inhibitor group had plasma HIV-1 RNA less than

149 of adverse events compared with five in the integrase inhibitor group.

150 Titration of PF74 against the integrase inhibitor raltegravir showed an additive antiv

151 y acquired significant resistance to APV, an integrase inhibitor raltegravir, and a GRL-09510 congene

152 289 were randomly assigned to receive the integrase inhibitor regimen and 286 to receive the prote

153 the safety and efficacy of the single tablet integrase inhibitor regimen containing elvitegravir, cob

154 citabine, and tenofovir disoproxil fumarate (integrase inhibitor regimen) or ritonavir-boosted atazan

155 have compared the safety and efficacy of any integrase inhibitor to efavirenz when initiated during p

156 h viral replication and raltegravir (RAL; an integrase inhibitor) suppression, mimicking active and A

157 a three-drug regimen that did not include an integrase inhibitor, future research should focus on par

158 significantly shorter in those receiving an integrase inhibitor- versus a protease inhibitor-based r

159 individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy.

160 in PLWH treated with newer drugs (including integrase inhibitor-based regimens), with fat gain due t

161 ion and might be better tolerated than other integrase inhibitor-based single-tablet regimens, but lo

162 ment is associated with long-term failure of integrase inhibitor-containing first-line regimens, and

163 Impact of Integrase-inhibitor DOlutegravir On the viral Reservoir

164 genotypes exclude testing for resistance to integrase inhibitors ("IR testing"), although this class

165 therapy regimens were predominantly based on integrase inhibitors (51.96%).

166 ARV regimens were predominantly based on integrase inhibitors (51.96%).

167 inding to the viral RNA genome by allosteric integrase inhibitors (ALLINIs) or through mutations with

168 f HIV-1 integrase inhibitors, the allosteric integrase inhibitors (ALLINIs), engage integrase distal

169 , 1.76 per 10 U/L; P < .01), and exposure to integrase inhibitors (aOR, 1.28 per year; P = .02) were

170 lability were analyzed for NTD reports for 4 integrase inhibitors (DTG, raltegravir, elvitegravir, bi

171 TIs (NNRTIs), protease inhibitors (PIs), and integrase inhibitors (IIs) did not affect HK2, except fo

172 ed the prevalence of PDDIs in the era of HIV integrase inhibitors (INIs), characterized by more favor

173 leoside reverse transcriptase inhibitors and integrase inhibitors (without cobicistat).

174 The potency of integrase inhibitors against 3'-processing and their abi

175 well as the promises and challenges of using integrase inhibitors for HIV/AIDS management.

176 need to accelerate the study and approval of integrase inhibitors for use in young children.

177 deficiency virus (HIV) treatments containing integrase inhibitors is unknown.

178 first ART regimens or regimens that include integrase inhibitors or two drugs.

179 Allosteric HIV-1 integrase inhibitors promote aberrant IN multimerization

180 virine, ritonavir-boosted lopinavir, and the integrase inhibitors raltegravir and elvitegravir.

181 Although antiretroviral regimens containing integrase inhibitors rapidly suppress HIV viral load in

182 No resistance to integrase inhibitors was identified in patients receivin

183 Although integrase inhibitors were the last among this group to b

184 A separate class of HIV-1 integrase inhibitors, the allosteric integrase inhibitor

185 e (PDR) on the efficacy of second generation integrase inhibitors.

186 tion with clinical reverse transcriptase and integrase inhibitors.

187 to CAB and cross-resistance to all licensed integrase inhibitors.

188 Integron integrases innovated from double-strand- toward single-s

189 HK022 coliphage site-specific recombinase Integrase (Int) can catalyze integrative site-specific r

190 tion is mediated by a non-canonical tyrosine integrase (Int) lacking an N-terminal domain typically a

191 Streptomyces phage C31 integrase (Int)-a large serine site-specific recombinase

192 In these models, integrase interaction captures features of the relative

193 phaScreen binding assays, revealing that the integrase interacts with the N-terminal half of TRN-SR2

194 his transition was possible, we have evolved integrase IntI1 to what should correspond to an early in

195 The split-intein integrase is a potentially versatile, regulatable compon

196 The phage-derived phiC31 integrase is a useful tool for mediating sequence-specif

197 EDGF) and human immunodeficiency virus (HIV) integrase is an important possible strategy for anti-vir

198 d residue Q146 in the flexible loop of HIV-1 integrase is critical for productive viral DNA binding t

199 A useful feature of serine integrases is the simple regulation and unidirectionalit

200 iscovery of a fully programmable, RNA-guided integrase lays the foundation for genomic manipulations

201 efficiently cleaved in vitro by recombinant integrases, leading to the formation of linear 3'-proces

202 actively transcribed euchromatin, where the integrase-LEDGF/p75 interaction drives integration into

203 Here, we show for the Listeria innocua integrase (LI Int) system that the CC domain promotes se

204 on-coordinating residue within a novel viral integrase-like zinc finger domain.

205 This minimal integrase may represent the function of the ancestral Ca

206 ites within the COL1A locus to enable phiC31 integrase mediated introduction of transgenes has been g

207 be efficiently used as a substrate in HIV-1 integrase-mediated integration both in vitro and in euka

208 e on the many benefits of plasmids in phiC31 integrase-mediated transgenesis.

209 The individual domains of the eight integrase molecules play varying roles to hold the compl

210 action site and disrupt the structure of the integrase multimer that is required for the HIV-1 matura

211 Integrase mutations can reduce the effectiveness of the

212 We show integrase mutations G118R, E92G/Q, or G140R in plasma fr

213 The integrase octamer solves a conundrum for betaretroviruse

214 ecognition of NSD3, LANA of herpesvirus, and integrase of MLV, which involves formation of an intermo

215 eated healthy rhesus macaques with protease, integrase, or reverse transcriptase inhibitors for 1 to

216 decreases nonspecific activity of Cas1-Cas2 integrase outside the leader-proximal region of a CRISPR

217 x, p17), reverse transcriptase (p66/51), and integrase (p31) were serially measured using quantitativ

218 sertion elements, transposons, prophages and integrases - paying testament to past genomic promiscuit

219 resultant IGEs from 2168 genomes, along with integrase phylogenetic analysis and gene inactivation te

220 The retroviral enzyme integrase plays an essential role in the virus replicati

221 e direct interaction between TRN-SR2 and HIV integrase predominantly involves the catalytic core doma

222 Serine integrases promote recombination between two different D

223 The integrase promotes unidirectional DNA exchange between a

224 We describe preparation of phiC31 integrase protein and evidence that it can mediate genom

225 s that focus on cellular components of viral integrase protein interactions can be used to combat the

226 We found that the integrase protein of IDLV mediated the highly efficient

227 f 605- and 613-amino-acid versions of phiC31 integrase protein to mediate efficient, site-specific in

228 ped a replication-competent MLV in which the integrase protein was tagged with a FLAG epitope.

229 ic process is catalyzed by the virus-encoded integrase protein, which is conserved among retroviruses

230 Unlabelled RAP1 GTPase and HIV integrase proteins were selectively detected from variou

231 efficiency and single-protein convenience of integrase-RDF fusion proteins make them potentially very

232 everse reactions using the integrase and the integrase-RDF fusion, respectively.

233 or changes in the length and sequence of the integrase-RDF linker peptide did not affect fusion prote

234 -Recombination Directionality Factor fusion (Integrase-RDF) that efficiently catalysed the reverse at

235 n directionality factor (RDF) in addition to integrase; RDF activates attL x attR recombination and i

236 ese results explain how the Cas1-Cas2 CRISPR integrase recognizes a sequence-dependent DNA structure

237 ins to control the reconstitution of a split Integrase-Recombination Directionality Factor fusion (In

238 Switching to alternative unboosted integrase regimens should be considered for patients wit

239 Switching to alternative unboosted integrase regimens should be considered for patients wit

240 y with single-copy sensitivity targeting the integrase region of HIV-1 (integrase single-copy assay [

241 he integrase, we studied the impact of minor integrase resistance mutations.

242 (HIV-1) protease, reverse transcriptase, and integrase sequences-three genes that are commonly sequen

243 ity targeting the integrase region of HIV-1 (integrase single-copy assay [iSCA] v1.0) has been widely

244 sidual plasma viremia was measured using the integrase single-copy assay.

245 With integrase strand inhibitor (INSTI)-based regimens now re

246 core, we have designed and synthesized a new integrase strand transfer (INST) inhibitor type featurin

247 rse-transcriptase inhibitor (43%), NRTI plus integrase strand transfer inhibitor (25%), and NRTI plus

248 oup experienced VF without resistance to the integrase strand transfer inhibitor (INSTI) class; 1 pat

249 t-line combination therapy that includes the integrase strand transfer inhibitor (INSTI) dolutegravir

250 ir (CAB) long-acting injectable (CAB LA), an integrase strand transfer inhibitor (INSTI), reduces dos

251 Integrase strand transfer inhibitor (INSTI)-based combin

252 older antiretroviral therapy (ART) to newer integrase strand transfer inhibitor (INSTI)-based regime

253 Integrase strand transfer inhibitor (InSTI)-based regime

254 The base case prevalence of transmitted integrase strand transfer inhibitor (INSTI)-resistant (I

255 The prevalence of integrase strand transfer inhibitor (INSTI)-transmitted

256 rse transcriptase inhibitors (NRTIs) plus an integrase strand transfer inhibitor (InSTI).

257 ranscriptase inhibitor (0.68 [0.51-0.90]) or integrase strand transfer inhibitor use (0.26 [0.13-0.53

258 Integrase strand transfer inhibitor use was associated w

259 Dolutegravir is a once-daily integrase strand transfer inhibitor with no need for pha

260 Cabotegravir (GSK1265744) is an HIV-1 integrase strand transfer inhibitor with potent antivira

261 , and tenofovir alafenamide is a once-daily, integrase strand transfer inhibitor-based regimen approv

262 n or now a 2-drug regimen, which includes an integrase strand transfer inhibitor.

263 me people living with HIV who are prescribed integrase strand transfer inhibitors (INSTI).

264 Integrase strand transfer inhibitors (INSTIs) are crucia

265 Integrase strand transfer inhibitors (INSTIs) are highly

266 Integrase strand transfer inhibitors (INSTIs) are now re

267 Integrase strand transfer inhibitors (INSTIs) are recomm

268 Integrase strand transfer inhibitors (InSTIs) are recomm

269 All recent treatment guidelines recommend integrase strand transfer inhibitors (INSTIs) as compone

270 Integrase strand transfer inhibitors (INSTIs) coadminist

271 Treatment initiation with integrase strand transfer inhibitors (INSTIs) has been a

272 Although some integrase strand transfer inhibitors (INSTIs) promote pe

273 Integrase strand transfer inhibitors (INSTIs) were assoc

274 iveness of the first-generation FDA-approved integrase strand transfer inhibitors (INSTIs), raltegrav

275 Integrase strand-transfer inhibitor (INSTI)-based antire

276 Integrase strand-transfer inhibitor (INSTI)-based antire

277 Testing for transmitted integrase strand-transfer inhibitor resistance is curren

278 Although second-generation HIV integrase strand-transfer inhibitors (INSTIs) are prescr

279 e latest generation of antiretroviral drugs, integrase strand-transfer inhibitors (INSTIs).

280 el, extended coiled-coil (CC) domains in the integrase subunits are proposed to interact in a way tha

281 se new methods to a recently reported manual integrase-targeting single-copy assay version 2 (iSCA v2

282 The allosteric inhibitors of integrase (termed ALLINIs) interfere with HIV replicatio

283 he viral DNA ends and structurally mimic the integrase tetramer of prototype foamy virus, and two fla

284 e we describe allosteric inhibitors of HIV-1 integrase that bind to the LEDGF/p75 interaction site an

285 29 as potent allosteric inhibitors of HIV-1 integrase that exhibited low nanomolar antiviral potency

286 ->serine (G140S) amino acid substitutions in integrase that result in clinical INSTI failure perturb

287 Using the Cas1-Cas2 integrase, the CRISPR-Cas microbial immune system stores

288 CRISPR-Cas systems depend on the Cas1-Cas2 integrase to capture and integrate short foreign DNA fra

289 antibody mimics the effect of binding of HIV integrase to LEDGF which is crucial for HIV propagation.

290 Molecular modeling of HIV-1 integrase, together with biochemical data, indicate that

291 rative vector in which the gene encoding the integrase was deleted to increase its stability, and (ii

292 The C31 integrase was split into two extein domains, and intein

293 To clarify the mechanism of DNA looping by integrase, we determined a 3.9 angstrom resolution struc

294 ta for the complex of TRN-SR2 with truncated integrase, we propose a molecular model of the complex.

295 a baseline genotypic resistance test of the integrase, we studied the impact of minor integrase resi

296 le that are involved in the interaction with integrase were identified using AlphaScreen binding assa

297 Integrases were identified in all but one HTVC019Pvirus

298 In addition, the G140S-Q148H (SH) mutant integrase, which has a reduced 3'-processing activity, b

299 Our findings support a model of a minimal integrase with an internal ruler mechanism that favors s

300 The leukotriene (LT) and wingless/integrase (Wnt) pathways have been implicated in remodel